The 21-valent pneumococcal conjugate vaccine V116 is well tolerated in adults living with HIV and induces immunity to all 21 ...
Phase 2 clinical study titled ‘A Phase 2, Randomized, Double-Blind, Active-Controlled, Dose-Finding Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants ...
Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 study titled ‘A Study to Learn About ...
The 19th News on MSN
The childhood vaccine schedule: What is it and why do we need one?
A series of recommended shots that health providers administer to children as they age has been a recent target of President ...
The Healthy @Reader's Digest on MSN
I Just Got the Pneumonia Vaccine, and I’m Only in my 30s—Here’s Why I Made the Decision
Eligibility for this vaccination is suddenly a timely question. A senior health editor reports on her real-time experience.
Shingles Vaccination Linked to Vascular Benefits With Breakthrough Infections and in People With HIV
Several observational analyses suggest higher cardiovascular and dementia risks in those with and without HIV who get ...
The adult-specific 21-valent pneumococcal conjugate vaccine was well tolerated and immunogenic across all 21 serotypes in patients with HIV infection.
Infectious disease researchers found the vaccine, used to prevent herpes zoster, or shingles, is also linked to lower risks ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 STRIDE-13 trial evaluating CAPVAXIVE® (Pneumococcal 21-valent Conjugate ...
Vaccine awareness, safety, and addressing misinformation are all important to improve adherence and public health outcomes, ...
The United States Adult Vaccine Market is projected to soar to US$ 11.10 billion by 2033, up from US$ 6.55 billion in 2024, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback